All congress activities

This poster, presented at SIMD 2026, describes interim results from the Phase 3 APHENITY Extension Study evaluating diet liberalization and health-related quality of life (HRQoL) in sepiapterin-treated individuals with phenylketonuria (PKU) who were receiving sapropterin at study entry

This infographic, which supports the poster presented at SIMD 2026, describes interim results from the Phase 3 APHENITY Extension Study evaluating diet liberalization and health-related quality of life (HRQoL) in sepiapterin-treated individuals with phenylketonuria (PKU) who were receiving sapropterin at study entry

This infographic, which supports the poster presented at GMDI 2026, highlights findings from the APHENITY extension study evaluating the long-term effects of sepiapterin treatment on dietary phenylalanine tolerance in children aged ≤2 years with phenylketonuria (PKU)

This poster, presented at GMDI 2026, highlights findings from the APHENITY extension study evaluating the long-term effects of sepiapterin treatment on dietary phenylalanine tolerance in children aged ≤2 years with phenylketonuria (PKU)

This poster, presented at SIMD 2026, highlights interim results from the Phase 3 APHENITY Extension Study evaluating the long-term safety and responsiveness of sepiapterin treatment in children aged ≤2 years with phenylketonuria (PKU)

This poster, originally given as an oral presentation at ACMG 2026, summarizes results from three Phase 3 clinical trials that assessed sepiapterin responsiveness in patients with phenylketonuria (PKU)

This ICIEM 2025 oral presentation provides an overview of the AMPLIPHY phase 3 study which compares the efficacy and safety of sepiapterin and sapropterin in children and adults with phenylketonuria (PKU)

This symposium, presented at ACMG 2025, summarizes the APHENITY study which assessed the effectiveness of sepiapterin on dietary Phe in a broad population of phenylketonuria (PKU) patients, and discusses the need for innovative treatment approaches

This symposium, presented at ICIEM 2025, provides an overview of sepiapterin as a treatment for phenylketonuria (PKU) and the current PKU disease landscape

This poster, presented at ACMG 2025, describes interim results from the ongoing APHENITY extension study, which evaluated the effect of sepiapterin on dietary Phe tolerance in a broad population of phenylketonuria (PKU) participants

This symposium, presented at SSEIM 2024, provides an overview of sepiapterin as a potential treatment for phenylketonuria (PKU) and its implications for patient management